Cargando…

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis

Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Kelly A., Shen, Jeanne, Rieger, Kerri, Wei, Mike T., Gubatan, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699508/ https://www.ncbi.nlm.nih.gov/pubmed/36447766 http://dx.doi.org/10.14309/crj.0000000000000881

Ejemplares similares

Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab
por: Marmor, Meghan, et al.
Publicado: (2023)

Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report
por: Kakiuchi, Toshihiko, et al.
Publicado: (2022)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report
por: Liu, Ailing, et al.
Publicado: (2022)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy
por: Pavlidis, Polychronis, et al.
Publicado: (2022)

Coexistence of pyoderma gangrenosum and sweet's syndrome in a patient with ulcerative colitis
por: Ajili, Faida, et al.
Publicado: (2015)

Sweet Syndrome, Not so Sweet during an Ulcerative Colitis Flare Especially When You Cannot Eat
por: Stead, Courtney, et al.
Publicado: (2021)

Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis
por: Uchida, Genta, et al.
Publicado: (2023)

Sweet’s syndrome and mucosal prolapse polyps in a male patient with ulcerative colitis
por: Zhao, Xixian, et al.
Publicado: (2021)

Ustekinumab pharmacokinetics after subcutaneous administration in swine model
por: Grabowski, Tomasz, et al.
Publicado: (2021)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Refractory Sweet's syndrome successfully treated with rituximab
por: Seminario-Vidal, Lucia, et al.
Publicado: (2015)

Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2021)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Sweet's Syndrome: A Case Report of a Rare Extraintestinal Manifestation of Ulcerative Colitis
por: Santos, Maria Inês, et al.
Publicado: (2022)

Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
por: Agusti-Mejias, Anna, et al.
Publicado: (2013)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

Sweet's syndrome in a patient with acute ulcerative colitis: presentation of a case and review of the literature.
por: Díaz-Peromingo, J. A., et al.
Publicado: (2001)

Treatment of recalcitrant disseminated ulcerative necrobiosis lipoidica with ustekinumab
por: McMullan, Patrick, et al.
Publicado: (2023)

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
por: Argüelles-Arias, Federico, et al.
Publicado: (2023)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
por: Petty, Amy J., et al.
Publicado: (2020)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Sweet's Syndrome Successfully Treated with Granulocyte and Monocyte Adsorption Apheresis
por: Fujii, Asami, et al.
Publicado: (2017)

Subcutaneous Sweet’s syndrome associated with the onset of Behcet’s disease()()
por: Vargas-Mora, Pablo, et al.
Publicado: (2021)

Successful Treatment of Refractory Autoimmune Enteropathy With Ustekinumab
por: Scheid, Johannes F., et al.
Publicado: (2021)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review
por: Shi, Liping, et al.
Publicado: (2023)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mrucv9rmt1d5qqr84sijpjoq1u